FDA grants conditional acceptance of LYRFIGTU brand name
Elevar Therapeutics says the FDA granted conditional acceptance of LYRFIGTU as the brand name for lirafugratinib, which is under FDA Priority Review.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.